Angle locks in $250,000 contract with Eisai
Angle
9.35p
16:55 20/12/24
Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.
FTSE AIM All-Share
710.60
17:04 20/12/24
Support Services
10,602.77
17:14 20/12/24
Angle said on Tuesday that it will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study.
The AIM-listed group highlighted that success in the pilot study also offered the potential for "multiple large-scale follow-up studies". HER2-low breast cancer accounts for 55% of all breast cancer cases, with analysts predicting that the global HER2+ breast cancer ADC market will reach $3.3bn per annum by 2030,
Chief executive Andrew Newland said: "The use of CTC biomarkers in clinical trials is a rapidly growing field enabling longitudinal monitoring of genomic, transcriptomic and proteomic changes. Angle's Portrait HER2 assay provides a way to evaluate HER2 status in patients where a tissue biopsy at the metastatic site either fails or is not feasible.
"We are delighted that Eisai is utilising our new HER2 assay for this study and believe that a successful pilot study will lead the way to major expansion of this line of our business going forward."
As of 0900 GMT, Angle shares were up 1.70% at 11.95p.
Reporting by Iain Gilbert at Sharecast.com